Ann: AusCann Receives Positive MOC from the U.S. FDA for CPAT-01, page-35

Hi,

Until now, Layton has kept his promises he made after the merger.

But itit seems like the market expects a raise af new capital, which means a massive dilution with millions of new shares.

My hope is still that reducing the costs with generation a cash flow (Dermacan) can avoid this.

But if AusCann need cash, what a about bonds or something else to bridge the time until CPAT1 is ready, which could be our cash cow.

For me it seems like a better solution to raise cash than a massive dilution which is deadly for current shareholders, who are already sitting on a 50 percent loss or much more.